A mutual information-based in vivo monitoring of adaptive response to targeted therapies in melanoma.

ABSTRACT: The mechanisms of adaptive resistance to genetic-based targeted therapies of solid malignancies have been the subject of intense research. These studies hold great promise for finding co-targetable hub/pathways which in turn would control the downstream non-genetic mechanisms of adaptive resistance. Many such mechanisms have been described in the paradigmatic BRAF-mutated melanoma model of adaptive response to BRAF inhibition. Currently, a major challenge for these mechanistic studies is to confirm in vivo, at the single-cell proteomic level, the existence of dependencies between the co-targeted hub/pathways and their downstream effectors. Moreover, the drug-induced in vivo modulation of these dependencies needs to be demonstrated. Here, we implement such single-cell-based in vivo expressi

SUBMITTER: Bugi-Marteyn A 

PROVIDER: S-EPMC8267495 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature